Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Apr;105(4):771–772. doi: 10.1111/j.1476-5381.1992.tb09054.x

A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril.

W Linz 1, B A Schölkens 1
PMCID: PMC1908688  PMID: 1324047

Abstract

To evaluate the role of bradykinin in the antihypertrophic effect of the angiotensin-converting enzyme (ACE) inhibitor, ramipril, we investigated the influence of HOE 140, a specific B2-receptor antagonist, on the effects of ramipril on left ventricular hypertrophy (LVH) in rats with aortic banding. Ramipril at a dose of 1 mg kg-1 day-1 for 6 weeks prevented the increase in blood pressure and development of LVH after aortic banding; plasma ACE activity was significantly inhibited. A lower dose of ramipril (10 micrograms kg-1 day-1 for 6 weeks) had no effect on the increase in blood pressure or on plasma ACE activity, but prevented LVH after aortic banding. The antihypertrophic effects of the higher and the lower dose ramipril, as well as the antihypertensive action of the higher dose of ramipril were abolished by the coadministration of HOE 140 (500 micrograms kg-1 day-1). The present data show for the first time that the beneficial effects of an ACE-inhibitor on LVH in rats with hypertension caused by aortic banding can be prevented by a specific B2-receptor antagonist.

Full text

PDF
771

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Danckwardt L., Shimizu I., Bönner G., Rettig R., Unger T. Converting enzyme inhibition in kinin-deficient brown Norway rats. Hypertension. 1990 Oct;16(4):429–435. doi: 10.1161/01.hyp.16.4.429. [DOI] [PubMed] [Google Scholar]
  2. Garg U. C., Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989 May;83(5):1774–1777. doi: 10.1172/JCI114081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Linz W., Henning R., Schölkens B. A. Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats. J Hypertens Suppl. 1991 Dec;9(6):S400–S401. [PubMed] [Google Scholar]
  4. Linz W., Schölkens B. A., Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens A. 1989;11(7):1325–1350. doi: 10.3109/10641968909038172. [DOI] [PubMed] [Google Scholar]
  5. Schelling P., Fischer H., Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens. 1991 Jan;9(1):3–15. [PubMed] [Google Scholar]
  6. Shirotani M., Yui Y., Hattori R., Kawai C. U-61,431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells. Prostaglandins. 1991 Feb;41(2):97–110. doi: 10.1016/0090-6980(91)90023-9. [DOI] [PubMed] [Google Scholar]
  7. Wiemer G., Schölkens B. A., Becker R. H., Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 1991 Oct;18(4):558–563. doi: 10.1161/01.hyp.18.4.558. [DOI] [PubMed] [Google Scholar]
  8. Wirth K., Hock F. J., Albus U., Linz W., Alpermann H. G., Anagnostopoulos H., Henk S., Breipohl G., König W., Knolle J. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991 Mar;102(3):774–777. doi: 10.1111/j.1476-5381.1991.tb12249.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES